Avalo Therapeutics, Inc. (AVTX) Return on equity 2016–2025
Avalo Therapeutics, Inc. (AVTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-94.2%FY2025 · since FY2016: -7957.2% → -94.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -94.2% | -67.8 pp |
| FY2024 | -26.4% | +405.5 pp |
| FY2023 | -431.9% | — |
| FY2021 | -365.5% | -107.0 pp |
| FY2020 | -258.5% | -182.0 pp |
| FY2019 | -76.6% | +115.0 pp |
| FY2018 | -191.6% | -234.2 pp |
| FY2017 | 42.6% | +7999.8 pp |
| FY2016 | -7957.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice